Details
Stereochemistry | ACHIRAL |
Molecular Formula | C15H17NO2.C6H8O7 |
Molecular Weight | 435.4245 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)CC(O)(CC(O)=O)C(O)=O.COC1=CC2=C(CCNC(C)=O)C=CC=C2C=C1
InChI
InChIKey=JPAYITIGCPEZCD-UHFFFAOYSA-N
InChI=1S/C15H17NO2.C6H8O7/c1-11(17)16-9-8-13-5-3-4-12-6-7-14(18-2)10-15(12)13;7-3(8)1-6(13,5(11)12)2-4(9)10/h3-7,10H,8-9H2,1-2H3,(H,16,17);13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)
Molecular Formula | C6H8O7 |
Molecular Weight | 192.1235 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C15H17NO2 |
Molecular Weight | 243.301 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/24724693Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/12750432 | https://www.ncbi.nlm.nih.gov/pubmed/12764576 | http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000915/WC500046227.pdf
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24724693
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/12750432 | https://www.ncbi.nlm.nih.gov/pubmed/12764576 | http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000915/WC500046227.pdf
Agomelatine behaves both as a potent agonist at melatonin MT1 and MT2 receptors and as a neutral antagonist at 5-HT2C receptors. Accumulating evidence in a broad range of experimental procedures supports the notion that the psychotropic effects of agomelatine are due to the synergy between its melatonergic and 5-hydroxytryptaminergic effects. Agomelatine is indicated for the treatment of major depressive episodes.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1945 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24724693 |
0.1 nM [Ki] | ||
Target ID: CHEMBL1946 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24724693 |
0.12 nM [Ki] | ||
Target ID: CHEMBL225 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24724693 |
6.2 null [pKi] | ||
Target ID: CHEMBL1833 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24724693 |
6.6 null [pKi] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | VALDOXAN Approved UseTreatment of major depressive episodes. Launch Date1.23491516E12 |
PubMed
Title | Date | PubMed |
---|---|---|
New antidepressants or more of the same? | 2007 |
|
Role of the melatonin system in the control of sleep: therapeutic implications. | 2007 |
|
The phase shift hypothesis for the circadian component of winter depression. | 2007 |
|
Hippocampal neurogenesis, depressive disorders, and antidepressant therapy. | 2007 |
|
Agomelatine and its therapeutic potential in the depressed patient. | 2007 Aug |
|
Agomelatine: a novel atypical antidepressant. | 2007 Dec |
|
A review of the efficacy and tolerability of agomelatine in the treatment of major depression. | 2007 Dec |
|
Non-REM sleep instability in patients with major depressive disorder: subjective improvement and improvement of non-REM sleep instability with treatment (Agomelatine). | 2007 Dec |
|
[New hypnotics: perspectives from sleep physiology]. | 2007 Jul-Aug |
|
Gateways to clinical trials. | 2007 Jun |
|
Gateways to clinical trials. | 2007 May |
|
Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. | 2007 Nov |
|
The interaction between the internal clock and antidepressant efficacy. | 2007 Oct |
|
High-quality remission: potential benefits of the melatonergic approach for patients with major depressive disorder. | 2007 Oct |
|
Evidence of agomelatine's antidepressant efficacy: the key points. | 2007 Oct |
|
Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data. | 2007 Sep |
|
Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine. | 2007 Sep |
|
[Pharmacotherapy of depression: recent developments]. | 2007 Sep 19 |
|
Cellular and molecular mechanisms in the long-term action of antidepressants. | 2008 |
|
Effects of different antidepressant treatments on the core of depression. | 2008 |
|
Core symptoms of major depressive disorder: relevance to diagnosis and treatment. | 2008 |
|
Promising avenues of therapeutics for bipolar illness. | 2008 |
|
Melatonin receptor agonists: SAR and applications to the treatment of sleep-wake disorders. | 2008 |
|
Agomelatine: AGO 178, AGO178, S 20098. | 2008 |
|
Melatonergic drugs in clinical practice. | 2008 |
|
Gateways to clinical trials. | 2008 Apr |
|
Agomelatine treatment of major depressive disorder. | 2008 Dec |
|
Jet lag: therapeutic use of melatonin and possible application of melatonin analogs. | 2008 Jan-Mar |
|
A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. | 2008 Jun |
|
Agomelatine, a melatonin receptor agonist with 5-HT(2C) receptor antagonist properties, protects the developing murine white matter against excitotoxicity. | 2008 Jun 24 |
|
Melatonin and its agonists: an update. | 2008 Oct |
|
Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. | 2008 Oct |
|
Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data. | 2008 Sep |
|
Addressing circadian rhythm disturbances in depressed patients. | 2008 Sep |
|
Innovation translates into antidepressant effectiveness. | 2008 Sep |
|
Agomelatine, an innovative pharmacological response to unmet needs. | 2008 Sep |
|
Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system. | 2008 Sep |
|
Melatonin receptor agonist agomelatine: a new drug for treating unipolar depression. | 2009 |
|
Insomnia in patients with depression: some pathophysiological and treatment considerations. | 2009 |
|
Melatonin and melatonergic drugs on sleep: possible mechanisms of action. | 2009 |
|
Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action. | 2009 |
|
Chronic mild stress (CMS) in mice: of anhedonia, 'anomalous anxiolysis' and activity. | 2009 |
|
The effect of melatonergic and non-melatonergic antidepressants on sleep: weighing the alternatives. | 2009 |
|
The antidepressant agomelatine blocks the adverse effects of stress on memory and enables spatial learning to rapidly increase neural cell adhesion molecule (NCAM) expression in the hippocampus of rats. | 2009 Apr |
|
Pathophysiology of depression: role of sleep and the melatonergic system. | 2009 Feb 28 |
|
Influence of the novel antidepressant and melatonin agonist/serotonin2C receptor antagonist, agomelatine, on the rat sleep-wake cycle architecture. | 2009 Jul |
|
Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. | 2009 Jun |
|
Agomelatine improves symptoms of generalised anxiety disorder. | 2009 May |
|
Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders. | 2009 Winter |
|
Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale. | 2010 Jan |
Sample Use Guides
The recommended dose is 25 mg once daily taken orally at bedtime.
After two weeks of treatment, if there is no improvement of symptoms, the dose may be increased to
50 mg once daily, i.e. two 25 mg tablets, taken together at bedtime.
Decision of dose increase has to be balanced with a higher risk of transaminases elevation. Any dose
increase to 50 mg should be made on an individual patient benefit/risk basis and with strict respect of
LFT monitoring.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27269050
hypothalamic suprachiasmatic nucleus firing rates were dose-dependently suppressed by 19.2-80.9% following perfusion of 0.04-0.32mM agomelatine (p<0.001, IC50=0.14mM).
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 16:37:21 UTC 2023
by
admin
on
Sat Dec 16 16:37:21 UTC 2023
|
Record UNII |
A17BS39YWR
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
A17BS39YWR
Created by
admin on Sat Dec 16 16:37:21 UTC 2023 , Edited by admin on Sat Dec 16 16:37:21 UTC 2023
|
PRIMARY | |||
|
1403960-81-5
Created by
admin on Sat Dec 16 16:37:21 UTC 2023 , Edited by admin on Sat Dec 16 16:37:21 UTC 2023
|
PRIMARY | |||
|
100000172035
Created by
admin on Sat Dec 16 16:37:21 UTC 2023 , Edited by admin on Sat Dec 16 16:37:21 UTC 2023
|
PRIMARY | |||
|
66574442
Created by
admin on Sat Dec 16 16:37:21 UTC 2023 , Edited by admin on Sat Dec 16 16:37:21 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |